Search Result

Isoforms Recommended:	VEGFR2/KDR/Flk-1

Results for "

VEGFR-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	VEGFR (435) 11β-HSD (2) Acetyl-CoA Carboxylase (2) Akt (28) AMPK (5) Anaplastic lymphoma kinase (ALK) (3) Antibiotic (2) Apoptosis (142) Atg8/LC3 (2) Aurora Kinase (7) Autophagy (46) Bacterial (5) Bcl-2 Family (15) Bcr-Abl (5) Btk (1) c-Fms (14) c-Kit (39) c-Met/HGFR (30) Cadherin (2) Cannabinoid Receptor (1) Carbonic Anhydrase (7) Casein Kinase (2) Caspase (20) CDK (13) Checkpoint Kinase (Chk) (2) Complement System (3) COX (4) Cytochrome P450 (2) Dihydrofolate reductase (DHFR) (2) Discoidin Domain Receptor (2) Dopamine Receptor (4) Drug Derivative (3) Drug Intermediate (1) Drug Metabolite (4) EGFR (43) Endogenous Metabolite (7) Environmental Pollutants (1) Ephrin Receptor (6) ERK (18) Estrogen Receptor/ERR (1) FAK (5) Ferroptosis (13) FGFR (49) FLT3 (36) Fungal (2) GSK-3 (3) HDAC (5) HIF/HIF Prolyl-Hydroxylase (2) Histamine Receptor (1) HIV (1) HSP (2) HSV (3) IAP (1) IKK (1) Insulin Receptor (4) Integrin (4) Interleukin Related (3) IRE1 (7) Isotope-Labeled Compounds (15) JAK (2) JNK (2) Keap1-Nrf2 (2) Liposome (5) LRRK2 (1) Macrophage migration inhibitory factor (MIF) (1) MAP3K (2) MDM-2/p53 (8) MEK (5) Microtubule/Tubulin (9) Mitophagy (7) Mitosis (1) Mixed Lineage Kinase (2) MMP (3) mTOR (11) Necroptosis (3) NF-κB (5) NOD-like Receptor (NLR) (2) P-glycoprotein (1) p38 MAPK (7) Parasite (2) PARP (7) PD-1/PD-L1 (2) PDGFR (82) PERK (3) Phosphodiesterase (PDE) (1) PI3K (17) Pim (1) PKC (1) PROTACs (5) Raf (17) Ras (2) Reactive Oxygen Species (ROS) (13) Reference Standards (54) RET (15) Sialyltransferase (1) Small Interfering RNA (siRNA) (3) Src (22) STAT (8) STING (2) Survivin (1) Syk (1) TAM Receptor (11) Telomerase (1) Tie (12) TNF Receptor (1) Topoisomerase (5) Trk Receptor (6) Tyrosinase (1) Wee1 (2) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (427) Cardiovascular Disease (35) Endocrinology (2) Infection (17) Inflammation/Immunology (49) Metabolic Disease (11) Neurological Disease (20)
Oligonucleotides:	Pegylated Lipids (3) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

487

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: VEGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103002

SU5408 5 Publications Verification VEGFR2 Kinase Inhibitor I	VEGFR	Cardiovascular Disease
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of *VEGFR2* kinase with an IC₅₀ of 70 nM.

HY-160259

VEGFR-2-IN-39	PROTACs VEGFR	Cardiovascular Disease
VEGFR-2-IN-39 (PROTAC-5) is a PROTAC targeting *VEGFR-2* (IC₅₀: 208.6 nM). VEGFR-2-IN-39 has low toxicity.VEGFR-2-IN-39 inhibits the proliferation of EA.hy926, one of HUVECs, in a concentration-dependent manner, with an IC₅₀ of 38.65 µM .

HY-147133

VEGFR2-IN-2	VEGFR	Cancer
VEGFR2-IN-2 (compound 6e) is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

HY-18625A

VEGFR-2-IN-5 hydrochloride	VEGFR	Cancer
VEGFR-2-IN-5 hydrochloride is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

HY-149024

VEGFR-2-IN-23	VEGFR Apoptosis MDM-2/p53	Cancer
VEGFR-2-IN-23 (compound 11b) is a potent and selective *VEGFR-2* inhibitor with an IC₅₀ value of 0.34 nM. VEGFR-2-IN-23 shows antitumor activity. VEGFR-2-IN-23 induces apoptosis and cell cycle arrest at G1 phase .

HY-178453

VEGFR-2-IN-74	VEGFR Apoptosis	Cancer
VEGFR-2-IN-74 (compound 55) is a potent *VEGFR-2* inhibitor (IC₅₀ = 0.035 µM). VEGFR-2-IN-74 exhibits good anti proliferative activity and can induce apoptosis in various cancer cells, such as A549 (IC₅₀ = 2.67 µM) and HCT116 (IC₅₀ = 10.87 µM) cells. VEGFR-2-IN-74 has low toxicity to normal cells. VEGFR-2-IN-74 shows significant anti angiogenic effects in chicken embryo models. VEGFR-2-IN-74 can be used in the research of cancer .

HY-146236

VEGFR-2-IN-27	VEGFR	Cancer
VEGFR-2-IN-27 (compound 7a) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer .

HY-18625

VEGFR-2-IN-5	VEGFR	Cancer
VEGFR-2-IN-5 is a *VEGFR2* inhibitor extracted from patent WO2013055780A1, Page 69 .

HY-131658

VEGFR-2-IN-6	VEGFR	Others
VEGFR-2-IN-6 (example 64) is a *VEGFR2* inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110 .

HY-112337

VEGFR-2-IN-44	VEGFR PDGFR	Cancer
VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC₅₀ value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC₅₀ of 920 nM .

HY-175019

VEGFR-2-IN-70	VEGFR Apoptosis Caspase MDM-2/p53 Bcl-2 Family	Cancer
VEGFR-2-IN-70 is a potent *VEGFR-2* inhibitor with an IC₅₀ of 18.04 nM. VEGFR-2-IN-70 exhibits cytotoxicity against A549 and MCF-7 cancer cells with IC₅₀ values of 0.43 μM and 3.8 μM, respectively. VEGFR-2-IN-70 induces G1 cell cycle arrest and apoptosis in lung cancer cells. VEGFR-2-IN-70 is useful in cancer research .

HY-147926

VEGFR-2-IN-28	VEGFR Apoptosis	Cancer
VEGFR-2-IN-28 (compound 12c) is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.83 µM. VEGFR-2-IN-28 induces apoptosis and has anticancer activity .

HY-147902

VEGFR-2-IN-24	VEGFR	Cancer
VEGFR-2-IN-24 is a potent *VEGFR-2* inhibitor with IC₅₀ value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research .

HY-155610

VEGFR-2-IN-32	VEGFR	Cancer
VEGFR-2-IN-32 (Comp 3a) is an inhibitor of *VEGFR-2* with an IC₅₀ of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC₅₀ of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research .

HY-178968

VEGFR-2-IN-76	VEGFR	Cancer
VEGFR-2-IN-76 (Compound GL-3) is a potent *VEGFR-2* inhibitor with an IC₅₀ value of 5.44 μM. VEGFR-2-IN-76 can be used for cancer research .

HY-155464

VEGFR-2/AURKA-IN-1	VEGFR Aurora Kinase	Cancer
VEGFR-2/AURKA-IN-1 (compound 5e) is a thiazolidin-4-one derivative with antiglioma activity (IC₅₀: 6.43 μM, LN229). VEGFR-2/AURKA-IN-1 has affinity for AURKA and VEGFR-2 and is a potential ligand. VEGFR-2/AURKA-IN-1 causes DNA strand breaks and exhibits cytotoxic and anticancer potential .

HY-178004

VEGFR-2-IN-73	VEGFR Apoptosis	Cancer
VEGFR-2-IN-73 is a potent and selective *VEGFR-2* inhibitor, showing selectively inhibition of VEGFR-2 (IC₅₀ = 0.0787 μM) over EGFR (IC₅₀ = 1.31 μM). VEGFR-2-IN-73 demonstrates potent antiproliferative activity across multiple cancer cell lines. VEGFR-2-IN-73 induces G2/M and Pre-G1 phase arrest and significantly enhances apoptosis. VEGFR-2-IN-73 can be used in cancer research, such as colorectal carcinoma, hepatocellular carcinoma, and breast cancer .

HY-179046

VEGFR-2-IN-78	VEGFR	Cancer
VEGFR-2-IN-78 (Compound 6b) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.21 μM. VEGFR-2-IN-78 exhibits selective cytotoxicity against A-498 and MDA-MB-231 cells. VEGFR-2-IN-78 has antioxidant activity. VEGFR-2-IN-78 can be used in anti-angiogenesis research .

HY-145864

VEGFR-2-IN-12	VEGFR	Cancer
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.037 µM. VEGFR-2-IN-12 shows high growth inhibition against MCF-7 cells (GI₅₀=1.6 µM). VEGFR-2-IN-12 has antitumor activity .

HY-155242

VEGFR-2-IN-36	VEGFR Bcl-2 Family Apoptosis	Cancer
VEGFR-2-IN-36 (compound 15) is a VEGFR-2 inhibitor (IC₅₀: 0.067 μM) and inducer of apoptosis with anticancer activity. VEGFR-2-IN-36 upregulates BAX levels and downregulates Bcl-2 levels. VEGFR-2-IN-36 is toxic to cancer cells, MCF-7 (IC₅₀=0.42 μM) and HepG2 (IC₅₀=0.22 μM) .

HY-174324

VEGFR-2/P-gp-IN-1	VEGFR P-glycoprotein Apoptosis	Cancer
VEGFR-2/P-gp-IN-1, a Licochalcone A (HY-N0372) derivative, is an orally active *VEGFR-2* (IC₅₀ = 0.885 μM) and P-gp inhibitor. VEGFR-2/P-gp-IN-1 achieves anti-tumor proliferation and overcomes chemotherapy resistance by synchronously inhibiting VEGFR-2 kinase activity and P-gp drug efflux pump function. VEGFR-2/P-gp-IN-1 inhibits phosphorylation of VEGFR-2 and downstream PI3K/AKT signaling pathway proteins, induces apoptosis, blocks cells in the S phase, and inhibits invasive migration. VEGFR-2/P-gp-IN-1 exerts potent in vivo anti-tumor effects in the HeLa/DDP cell xenograft tumor model. VEGFR-2/P-gp-IN-1 is used in cervical cancer research.

HY-155239

VEGFR-2-IN-35	VEGFR	Cancer
VEGFR-2-IN-35 (compound 7) is a potent VEGFR-2 inhibitor with IC₅₀=37 nM. VEGFR-2-IN-35 inhibits MCF-7 and HCT 116 cancer cells with IC₅₀ values of 10.56 and 7.07 μM, respectively .

HY-179032

VEGFR-2-IN-77	VEGFR PI3K Akt mTOR Apoptosis	Cancer
VEGFR-2-IN-77 (Compound 10) is a *VEGFR-2* inhibitor with an IC₅₀ value of 139 nM. VEGFR-2-IN-77 inhibits the PI3K/AKT/mTOR pathway. VEGFR-2-IN-77 exhibits selective cytotoxicity, being particularly sensitive to leukemia and prostate cancer cells. VEGFR-2-IN-77 causes cell cycle arrest and apoptosis, inhibiting cell migration and invasion. VEGFR-2-IN-77 can be used for the study of leukemia and prostate cancer.

HY-182306

VEGFR-2 ligand-2	VEGFR	Cardiovascular Disease
VEGFR-2 ligand-1, Sorafenib (HY-10201) derivative, is a vascular endothelial growth factor receptor 2 (VEGFR2) ligand. VEGFR-2 ligand-1 binds to the ATP-binding pocket of VEGFR2, forms hydrophobic contacts and hydrogen bonds with key binding-site residues. VEGFR-2 ligand-1 can be used for the research angiogenesis-related pathologies .

HY-159510

VEGFR-2-IN-51	Apoptosis VEGFR Microtubule/Tubulin Reactive Oxygen Species (ROS)	Cancer
VEGFR-2-IN-51 (compound 19) is an orally active dual-target inhibitor of *VEGFR-2* (IC₅₀=15.33 μM) and tubulin (IC₅₀=0.76 μM) with anti-tumor activity. VEGFR-2-IN-51 induces tumor cell apoptosis by reducing mitochondrial membrane potential and increasing reactive oxygen species (ROS) levels. VEGFR-2-IN-51 exerts anti-angiogenic effects by blocking the *VEGFR-2/PI3K/AKT* signaling pathway. In addition, VEGFR-2-IN-51 has significant anti-proliferative activity against the gastric cancer cell line MGC-803 (IC₅₀=0.005 μM) .

HY-18926

VEGFR2-IN-7	VEGFR	Cancer
VEGFR2-IN-7 (compound E) is an inhibitor of *VEGFR2. VEGFR2-IN-7* can used in study cancers .

HY-W800162

VEGFR-2-IN-37	VEGFR	Cancer
VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .

HY-145849

VEGFR2-IN-1	VEGFR	Cancer
VEGFR2-IN-1 is a potent and selective *VEGFR2* inhibitor (IC₅₀=19.8 nM). VEGFR2-IN-1 inhibits cell proliferation and migration through apoptosis activation and *VEGFR2* inhibition .

HY-149361

VEGFR2-IN-4	VEGFR	Inflammation/Immunology
VEGFR2-IN-4 (compound 25) is a potent and selective VEGFR2 kinase inhibitor, with a GI₅₀ of 0.7 nM. VEGFR2-IN-4 shows anti-angiogenic effect. VEGFR2-IN-4 can be used for the research of rheumatoid arthritis .

HY-162326

VEGFR-2-IN-41	VEGFR Apoptosis	Cancer
VEGFR-2 IN-41 (Compound 8) is a *VEGFR-2* inhibitor with an IC₅₀ of 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity .

HY-153158

VEGFR2-IN-3	VEGFR	Cancer
VEGFR2-IN-3 (compound 385) is a potent *VEGFR2* inhibitor .

HY-147872

VEGFR-2-IN-22	VEGFR Microtubule/Tubulin Apoptosis	Cancer
VEGFR-2-IN-22 (Compound 25) is a dual *VEGFR-2* and β-tubulin polymerization inhibitor with an IC₅₀ of 19.82 nM against VEGFR-2. VEGFR-2-IN-22 induces apoptosis .

HY-148040

VEGFR-2-IN-29	VEGFR	Cancer
VEGFR-2-IN-29 (Compound 5) is a *VEGFR-2* inhibitor with an IC₅₀ of 16.5 nM .

HY-162887

VEGFR-2-IN-53	VEGFR Apoptosis	Cancer
VEGFR-2-IN-53 (Compound 15w) is a *VEGFR-2* inhibitor with an IC₅₀ of 4.34 μM. VEGFR-2-IN-53 induces apoptosis by inhibiting *VEGFR-2* activity and preventing cell migration, thereby exhibiting anti-angiogenic effects. The IC₅₀ value of VEGFR-2-IN-53 for inhibiting MCF-7 cell growth is 3.87 μM. VEGFR-2-IN-53 can be used in cancer research .

HY-144804

VEGFR-2-IN-17	VEGFR	Cancer
VEGFR-2-IN-17 (Compound 15a) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .

HY-144803

VEGFR-2-IN-16	VEGFR	Cancer
VEGFR-2-IN-16 (Compound 15b) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .

HY-147800

VEGFR-2-IN-21	VEGFR	Cancer
VEGFR-2-IN-21 (Compound 5d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity .

HY-169516

VEGFR-2-IN-65	VEGFR	Cancer
VEGFR-2-IN-65 (Compound 07) is a *VEGFR-2* inhibitor. VEGFR-2-IN-65 has H-bond interactions with Cys180. VEGFR-2-IN-65 inhibits tube formation in HUVECs .

HY-144805

VEGFR-2-IN-18	VEGFR Apoptosis	Cancer
VEGFR-2-IN-18 (Compound 15d) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60 nM. VEGFR-2-IN-18 induces cell apoptosis. VEGFR-2-IN-18 shows antitumor activities .

HY-162557

VEGFR-2-IN-45	VEGFR	Cancer
VEGFR-2-IN-45 (compound 3j) is a potent inhibitor of *VEGFR*-2, with the IC₅₀ of 0.2 μM. VEGFR-2-IN-45 plays an important role in cancer research .

HY-145856

VEGFR-2-IN-11	VEGFR Apoptosis	Cancer
VEGFR-2-IN-11 (Compound 8h) is a potent *VEGFR-2* inhibitor with an IC₅₀ of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis .

HY-146229

VEGFR-2-IN-25	VEGFR	Cancer
VEGFR-2-IN-25 (compound 5d) is a highly potent *VEGFR-2* inhibitor with an IC₅₀ value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer .

HY-149630

VEGFR2/HDAC1-IN-1	VEGFR HDAC Apoptosis	Cancer
VEGFR2/HDAC1-IN-1 (compound 13) is a potent *VEGFR-2/HDAC* dual inhibitor, with IC₅₀s of 57.83 nM and 9.82 nM, respectively. VEGFR2/HDAC1-IN-1 arrests the cell cycle at the S and G2 phases, and induces apoptosis in HeLa cells. VEGFR2/HDAC1-IN-1 exhibits anti-angiogenic effect .

HY-146492

VEGFR-2/BRAF-IN-2	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .

HY-157960

VEGFR-2-IN-42	VEGFR	Cancer
VEGFR-2-IN-42 (compound 8c) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-42 shows anti-proliferative effect against MCF7 cells with the IC₅₀ of 25 µM .

HY-144795

VEGFR-2-IN-14	VEGFR Apoptosis	Cancer
VEGFR-2-IN-14 (Compound 5) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-14 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis .

HY-144796

VEGFR-2-IN-15	VEGFR Apoptosis	Cancer
VEGFR-2-IN-15 (Compound 14b) is a potent *VEGFR-2* inhibitor. VEGFR-2-IN-15 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis .

HY-146491

VEGFR-2/BRAF-IN-1	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.049, 0.063 and 0.005 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-1 induces apoptosis and arrests the cell cycle mainly in the G1/S phase .

HY-146367

VEGFR-2-IN-19	VEGFR Apoptosis Reactive Oxygen Species (ROS)	Cancer
VEGFR-2-IN-19 (Compound 15b) is a potent *VEGFR2* inhibitor. VEGFR-2-IN-19 induces cell apoptosis and increases intracellular reactive oxygen species level. VEGFR-2-IN-19 can be used as an anticancer agent .

HY-170662

VEGFR-2-IN-62	Apoptosis Bcl-2 Family VEGFR	Cancer
VEGFR-2-IN-62 (Compound 3f) is an effective *VEGFR-2* inhibitor with an IC₅₀ value of 0.0557 μM. VEGFR-2-IN-62 can inhibit cell proliferation and induce apoptosis, and can be used in cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0451A

Dopamine hydrochloride 20+ Cited Publications ASL279	Microorganisms Phenols Polyphenols Endogenous metabolite Source Classification	Dopamine Receptor Endogenous Metabolite Ferroptosis
Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-N0135

Tanshinone IIA Maximum Cited Publications 36 Publications Verification Dan Shen ketone	Quinones Classification of Application Fields Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants Naphthalene Quinones Disease Research Fields Source Classification Cancer	VEGFR
Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2*.

HY-B0451

Dopamine 20+ Cited Publications ASL279 free base	Phenols Polyphenols Endogenous metabolite	Dopamine Receptor Endogenous Metabolite Ferroptosis
Dopamine is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine plays several important roles in the brain and body . Dopamine acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-12686

5Z-7-Oxozeaenol 25+ Cited Publications FR148083; L783279; LL-Z 1640-2	Natural Products Monophenols Microorganisms Classification of Application Fields Phenols Inflammation/Immunology Disease Research Fields Source Classification	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-D0803

Thymoquinone 10+ Cited Publications	Quinones Classification of Application Fields Nigella sativa L. Ranunculaceae Benzene Quinones Plants Inflammation/Immunology Disease Research Fields	Apoptosis VEGFR PI3K Akt
Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the *VEGFR2-PI3K-Akt* pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation ^[2] .

HY-112234

L-Sepiapterin 1 Publications Verification Sepiapterin	Alkaloids Structural Classification Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
L-Sepiapterin (Sepiapterin), is a phenylalanine hydroxylase activator, is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 ^S6K-dependent VEGFR-2 expression. L-Sepiapterin can be used for the study of hyperphenylalaninemia ^[2].

HY-N0876

Arenobufagin 4 Publications Verification	Animals Classification of Application Fields Disease Research Fields Steroids Source Classification Cancer	Apoptosis Autophagy PI3K Akt mTOR PARP Caspase Atg8/LC3
Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit *VEGF*-mediated angiogenesis through suppression of VEGFR-2 signaling pathway ^[2].

HY-N0563

Alizarin 1 Publications Verification	Quinones Classification of Application Fields Anthraquinones Rubiaceae Other Diseases Phenols Polyphenols Plants Disease Research Fields Rubia cordifolia L. Source Classification	AMPK VEGFR PI3K Akt NF-κB Cytochrome P450
Alizarin is a natural dye. Alizarin can be extracted from the roots of madder plant. Alizarin activates AMPK and *VEGFR2/eNOS* pathway. Alizarin regulates PI3K/Akt and inhibits NF-κB pathway. Alizarin enhances CYP1A1 enzyme activity. Alizarin has protective effects on hypertension and vascular endothelial dysfunction. Alizarin has anti-tumor activity against multiple cancers including pancreatic cancer, breast cancer, osteosarcoma and liver cancer. Alizarin has been widely used as a pigment in textile fabrics and paintings ^[2] .

HY-N0883

Gamabufotalin 4 Publications Verification Gamabufagin	Structural Classification Animals Classification of Application Fields Disease Research Fields Steroids Source Classification Cancer	VEGFR
Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways.

HY-N0819

Raddeanin A 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, *VEGFR2, NLRP3* inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma ^[2] .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the *VEGFR-2* signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the *Nrf2-STING* signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of *11β-HSD2. Jujuboside B induces ferroptosis* and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes ^[2] .

HY-B0451AR

Dopamine hydrochloride (Standard) ASL279 (Standard)	Structural Classification Microorganisms Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards Dopamine Receptor Endogenous Metabolite Ferroptosis
Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-N0772

Isomangiferin 4 Publications Verification	Infection Structural Classification Liliaceae Xanthones Classification of Application Fields Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants Disease Research Fields Source Classification	VEGFR NOD-like Receptor (NLR) NF-κB Bacterial AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative
Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective *VEGFR-2* kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing ^[2] .

HY-N4322

Decursinol angelate 1 Publications Verification	Structural Classification Pseudognaphalium affine (D. Don) Anderberg Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Source Classification Cancer	PKC
Decursinol angelate acts as a PKC activator and GDH inhibitor, with an IC₅₀ of 1.432 μM against human GDH. Decursinol angelate activates PKC, downregulates PKCα and PKCβII isoforms, and exerts cytotoxic activity against cancer cells. Decursinol angelate binds to GDH and inhibits its enzymatic activity. Decursinol angelate inhibits *VEGF*-induced autophosphorylation of *VEGFR2, downstream p42/44 ERK* and JNK-MAPK signaling pathways, as well as the angiogenesis process. Decursinol angelate is applicable to research related to cancer and leukemia ^[2] .

HY-N3127

Orobol	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Isoflavones Source Classification	Casein Kinase PI3K VEGFR
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC₅₀=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC₅₀=3.46-5.27 μM for PI3K α/β/γ/K/δ) ^[2].

HY-Y0121

Ethyl cinnamate	Structural Classification Kaempferia galanga L. Classification of Application Fields Other Diseases Other Phenylpropanoids Phenylpropanoids Plants Disease Research Fields Source Classification Zingiberaceae	Environmental Pollutants Apoptosis Parasite VEGFR
Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating *VEGFR2* signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC₅₀ values of 0.30 mM and 0.38 mM in rat aorta ^[2] .

HY-N1408

trans-Trimethoxyresveratrol trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene	other families Stilbenes Classification of Application Fields Plants Disease Research Fields Source Classification Cancer	VEGFR Reactive Oxygen Species (ROS) Caspase Apoptosis
Trans-Trimethoxyresveratrol (trans-trismethoxy Resveratrol; (E)-Resveratrol trimethyl ether; trans-3,5,4'-Trimethoxystilbene) is an orally active natural derivative of Resveratrol (HY-16561). Trans-Trimethoxyresveratrol has an enhanced anticancer profile compared to Resveratrol, exhibiting higher potency than resveratrol, with improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, and increased apoptosis. Trans-Trimethoxyresveratrol causes microtubule disassembling and tubulin depolymerization and exerts anti-angiogenic effects through *VEGFR2*. Trans-Trimethoxyresveratrol can be used for the studies of anti-angiogenic and anti-cancer (such as non-small cell lung cancer and osteosarcoma) ^[2] .

HY-N8342

Rhamnazin 1 Publications Verification	Combretaceae Phenols Polyphenols Plants Combretum erythrophyllum Sond. Source Classification	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against *VEGFR2* kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties ^[2].

HY-N7177

Hydroxytanshinone IIA	Quinones Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Plants Naphthalene Quinones Disease Research Fields Cancer Source Classification	Drug Metabolite VEGFR
Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of *VEGF/VEGFR2* .

HY-N2666

5α-Hydroxycostic acid	Other Terpenoids Classification of Application Fields Terpenoids Erythrina burttii Baker f. Plants Compositae Disease Research Fields Cancer Source Classification	VEGFR
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating *VEGF/VEGFR2* and *Ang2/Tie2* pathways .

HY-N3001

Isolinderalactone 1 Publications Verification	Classification of Application Fields Terpenoids Sesquiterpenes Plants Lauraceae Lindera aggregata (Sims) Kosterm. Disease Research Fields Source Classification Cancer	STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits *VEGF* expression and tyrosine phosphorylation of *VEGFR2. Isolinderalactone decreases viability and induces apoptosis* in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury ^[2] .

HY-107417

Hypothemycin	Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Phenols Disease Research Disease Research Fields Source Classification Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[2].

HY-N6926

1,3,5-Tricaffeoylquinic acid	Infection Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Plants Disease Research Fields Source Classification	HIV Apoptosis Caspase VEGFR ERK PI3K Akt mTOR PARP
1,3,5-Tricaffeoylquinic acid acts as an angiogenesis inhibitor and apoptosis inducer, and exhibits anti-HIV activity. 1,3,5-Tricaffeoylquinic acid inhibits the phosphorylation of *VEGFR2, ERK, PI3K, Akt* and mTOR in the angiogenesis signaling pathway. 1,3,5-Tricaffeoylquinic acid regulates apoptosis-related proteins, upregulates the levels of activated caspase-8, Bax, activated PARP and caspase-3/9, while downregulates the level of *Bcl-2*. 1,3,5-Tricaffeoylquinic acid inhibits tube formation and shows cytotoxicity against ovarian cancer cells. 1,3,5-Tricaffeoylquinic acid can be used in studies related to ovarian cancer ^[2].

HY-D0803R

Thymoquinone (Standard)	Quinones Structural Classification Nigella sativa L. Ranunculaceae Benzene Quinones Plants	Reference Standards Apoptosis VEGFR PI3K Akt
Thymoquinone (Standard) is the analytical standard of Thymoquinone. This product is intended for research and analytical applications. Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation ^[2] .

HY-Y0121R

Ethyl cinnamate (Standard)	Structural Classification Kaempferia galanga L. Microorganisms Other Phenylpropanoids Phenylpropanoids Plants Source Classification Zingiberaceae	Reference Standards Parasite VEGFR Apoptosis
Ethyl cinnamate (Standard) is the analytical standard of Ethyl cinnamate. This product is intended for research and analytical applications. Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC₅₀ values of 0.30 mM and 0.38 mM in rat aorta ^[2] .

HY-N0135R

Tanshinone IIA (Standard) Dan Shen ketone (Standard)	Quinones Structural Classification Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants Naphthalene Quinones Source Classification	Reference Standards VEGFR
Tanshinone IIA (Standard) is the analytical standard of Tanshinone IIA. This product is intended for research and analytical applications. Tanshinone IIA (Tan IIA) is one of the main compositions in the root of Salvia miltiorrhiza Bunge. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.

HY-152120

(±)-Aiphanol Aiphanol	Phenols Polyphenols Arecaceae Plants Aiphanes aculeata Willd Source Classification	COX VEGFR
(±)-Aiphanol is a newly discovered stilbenolignan analog. (±)-Aiphanol exhibits significant anti-inflammatory activity, acting through inhibition of COX-1 and *COX-2. The inhibitory effect on COX-1 (IC₅₀ = 1.9 μM) is particularly strong, while the effect on COX-2 (IC₅₀= 9.9 μM) is relatively weak .(±)-Aiphanol effectively inhibits VEGFR2* (IC₅₀=0.92 μM). (±)-Aiphanol blocks angiogenesis and promotes apoptosis through inhibition of VEGFR2 and COX2 activity. (±)-Aiphanol is orally active ^[2].

HY-N0876R

Arenobufagin (Standard)	Structural Classification Animals Steroids Source Classification	Reference Standards Apoptosis Autophagy PI3K Akt mTOR PARP Caspase Atg8/LC3
Arenobufagin is a natural bufadienolide that can be extracted from toad venom. Arenobufagin can induce apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Arenobufagin has potent antineoplastic activity against HCC HepG2 cells as well as corresponding multidrug-resistant HepG2/ADM cells. Arenobufagin can inhibit VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway ^[2].

HY-W011873R

Palmitoleic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-W778608R

Quercetin 7-glucuronide (Standard) Quercetin 7-O-β-glucuronide (Standard)	Flavonols Flavonoids Pedaliaceae Plants Uncarina grandidieri (Baill.) Ihlenf. & Straka Source Classification	Drug Metabolite Reference Standards
Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-N0772R

Isomangiferin (Standard)	Structural Classification Liliaceae Xanthones Phenols Polyphenols Anemarrhena asphodeloides Bunge Plants Source Classification	Reference Standards VEGFR NF-κB NOD-like Receptor (NLR) AMPK Acetyl-CoA Carboxylase Apoptosis Reactive Oxygen Species (ROS) HSV Drug Derivative
Isomangiferin (Standard) is the analytical standard of Isomangiferin (HY-N0772). This product is intended for research and analytical applications. Isomangiferin is an orally active xanthone C-glucoside, and its chemical structure is similar to Mangiferin (HY-N0290). Isomangiferin is an effective *VEGFR-2* kinase inhibitor, which can induces cell apoptosis, inhibit the growth, metastasis and angiogenesis of breast cancer. Isomangiferin exerts anti-inflammatory effects by inhibiting the HMGB1/NLRP3/NF-κB signaling pathway, thereby improving the renal function indicators of diabetic mice. Isomangiferin exhibits inhibitory effects on various bacteria and herpes simplex virus type 1 (HSV-1). Isomangiferin promotes the migration and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and reduces cell apoptosis and the production of ROS by activating the AMPK/ACC pathway, thereby facilitating fracture healing.

HY-N0819R

Raddeanin A (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK
Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.

HY-N0883R

Gamabufotalin (Standard) Gamabufagin (Standard)	Structural Classification Animals Steroids Source Classification	Reference Standards VEGFR
Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways.

HY-117733

Zerumin A	Structural Classification Arecaceae Bercht. & J. Presl Ketones, Aldehydes, Acids Terpenoids Arecaceae Diterpenoids Plants Source Classification Zingiberaceae	Tie VEGFR
Zerumin A is an anti-angiogenic agent that acts on multiple molecular targets related to angiogenesis (including *kdr/VEGFR2, angpt1, angpt2, tie1, and tie2). Zerumin A specifically inhibits the proliferation and migration of human umbilical vein endothelial cells (HUVECs) by regulating the VEGF-VEGFR* and ANGPT-TIE signaling pathways, and dose-dependently inhibits angiogenesis (10-20 μM significantly inhibits zebrafish embryo angiogenesis). Zerumin A can be used in the research of cancer and angiogenesis-related inflammatory diseases. Zerumin A can be naturally extracted from the 95% ethanol extract of the fruits, seeds, and pericarp of Alpinia caerulea (R.Br.) Bentham (a plant of the Alpinia genus in the Zingiberaceae family) .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the *VEGFR-2* signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the *Nrf2-STING* signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of *11β-HSD2. Jujuboside B induces ferroptosis* and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Cat. No.	Product Name	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively ^[2] .

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀ values of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively ^[2].

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d₃) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively .

HY-B0451AS7

Dopamine-d5 hydrochloride

Dopamine-d₅ (hydrochloride) is the deuterium labeled Dopamine (hydrochloride). Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC₅₀=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC₅₀s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ ^[2] .

HY-12047S

Ponatinib-d8
Ponatinib-d₈ (AP24534-d₈) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation ^[2].

HY-10255AS

Sunitinib-d10
Sunitinib-d₁₀ (SU 11248-d₁₀) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation ^[2].

HY-15992S

BIBF 1202-13C,d3
BIBF 1202- ¹³C,d₃ is the ¹³C- and deuterium labeled BIBF 1202 (HY-15992). BIBF 1202 is the carboxylate metabolite of Nintedanib (HY-50904) which inhibits VEGFR2 kinase with an IC50 of 62 nM.

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively ^[2].

HY-W705479

Pazopanib-d3 hydrochloride
Pazopanib-d₃ (hydrochloride) (GW786034-d₃ (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208S2

Pazopanib-d3
Pazopanib-d₃ (GW786034-d₃) is deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-W749733

BIBF 1202-d3
BIBF 1202-d₃ is the deuterium labeled BIBF 1202 (HY-15992). BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC₅₀ of 62 nM.

HY-W701071

Vatalanib-d4
Vatalanib-d₄ (PTK787-d₄; ZK-222584-d₄; CGP-79787-d₄) is the deuterium labeled Vatalanib (HY-10203). Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC₅₀ of 37 nM.

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and EGFR/HER1 (IC₅₀=500 nM) .

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and EGFR/HER1 (IC₅₀=500 nM) ^[2].

HY-10260S2

Vandetanib-13C6
Vandetanib- ¹³C₆ is a ¹³C labeled Vandetanib (HY-10260) . Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) ^[2].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride . Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively ^[2] .

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib . Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively ^[2] .

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10201S4

Sorafenib-d3 tosylate

Sorafenib-d₃ (Donafenib-d₃) tosylate is the deuterium labeled Sorafenib (HY-10201). Sorafenib is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib-d3tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib-d3tosylate induces autophagy and apoptosis. Sorafenib-d3tosylate has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-Y0121S1

Ethyl cinnamate-d7

Ethyl cinnamate-d₇ is deuterated labeled Ethyl cinnamate (HY-Y0121). Ethyl cinnamate, an orally active chemical constituent of the rhizome of Kaempferia galanga, exhibits anti-cancer, nematocidal, sedative and vasorelaxant activities. Ethyl cinnamate is a fragrance ingredient used as a food flavor and additive for cosmetic products. Ethyl cinnamate is also an excellent clearing reagent for mammalian tissues. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer. Ethyl cinnamate inhibits the tonic contractions induced by high K+ and phenylephrine (PE) with respective IC50 values of 0.30 mM and 0.38 mM in rat aorta ^[2] .

Targets Recommended: VEGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for *VEGFR2, FGFR1, and PDGFRβ*, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks